Analysed CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ) News Sources
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain
30-04-2026
yahoo.com
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01-05-2026
yahoo.com
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
05-05-2026
yahoo.com
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet
08-05-2026
yahoo.com
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
11-05-2026
yahoo.com
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
12-05-2026
yahoo.com
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
15-05-2026
yahoo.com
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential
22-05-2026
marketbeat.com
What is the current price of CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ)?
The current price of CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ) is $13.32.
CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ) absolute price change since previous trading day?
The absolute price change of CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ) since the previous trading day is $-0.12.
CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ) percentage price change since previous trading day?
The percentage price change of CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ) since the previous trading day is -0.8929%.
What is the most recent average sentiment score for CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ)?
The most recent average sentiment score for CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ) is 62 out of 100.
What is the most recent average sentiment for CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ)?
The most recent sentiment for CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ) is .
SEC-8K** Filing Available For CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.